a 62176 has been researched along with carbostyril in 6 studies
| Studies (a 62176) | Trials (a 62176) | Recent Studies (post-2010) (a 62176) | Studies (carbostyril) | Trials (carbostyril) | Recent Studies (post-2010) (carbostyril) |
|---|---|---|---|---|---|
| 6 | 0 | 1 | 12,855 | 1,323 | 5,611 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, DT; Clement, JJ; Permana, PA; Plattner, JJ; Shen, LL; Snapka, RM | 1 |
| Fan, JY; Hurley, LH; Kerwin, SM; Sun, D; Yu, H | 1 |
| Hurley, LH; Kwok, Y; Zeng, Q | 1 |
| Hurley, LH; Kerwin, SM; Kwok, Y; Yu, H | 1 |
| Gleason-Guzman, M; Hurley, LH; Kim, MY; Na, Y; Vankayalapati, H | 1 |
| Choi, Y; Jeon, KH; Jun, KY; Kim, DK; Kim, HL; Kwon, Y; Na, Y | 1 |
6 other study(ies) available for a 62176 and carbostyril
| Article | Year |
|---|---|
Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Chlorocebus aethiops; DNA Replication; Doxorubicin; Kidney; Kinetics; Oxazines; Quinolones; Simian virus 40; Structure-Activity Relationship; Teniposide; Thymus Gland; Topoisomerase II Inhibitors | 1994 |
Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex.
Topics: Animals; Base Composition; Base Sequence; Binding Sites; Cattle; Deoxyribonuclease I; DNA; DNA Topoisomerases, Type II; Echinomycin; Electrophoresis, Agar Gel; Ethidium; Magnesium; Magnetic Resonance Spectroscopy; Manganese; Molecular Sequence Data; Molecular Structure; Oxazines; Oxygen; Quinolones; Spectrophotometry, Infrared; Structure-Activity Relationship | 1995 |
Structural insight into a quinolone-topoisomerase II-DNA complex. Further evidence for a 2:2 quinobenzoxazine-mg2+ self-assembly model formed in the presence of topoisomerase ii.
Topics: Antineoplastic Agents; Base Pair Mismatch; Base Sequence; Binding Sites; Binding, Competitive; DNA; DNA Topoisomerases, Type II; Hydrogen-Ion Concentration; Intercalating Agents; Models, Chemical; Molecular Sequence Data; Norfloxacin; Oxazines; Quinolones; Topoisomerase II Inhibitors; Ultraviolet Rays; Xanthenes; Xanthones | 1999 |
Efficient, Mg(2+)-dependent photochemical DNA cleavage by the antitumor quinobenzoxazine (S)-A-62176.
Topics: Aerobiosis; Anaerobiosis; Anti-Infective Agents; Antineoplastic Agents; Base Sequence; Binding Sites; Bleomycin; Deoxyribonuclease I; DNA; DNA Damage; Fluoroquinolones; Free Radical Scavengers; Free Radicals; Hydroxyl Radical; Magnesium; Methylene Blue; Models, Chemical; Molecular Sequence Data; Oxazines; Photosensitivity Disorders; Quinolones | 2000 |
Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Base Sequence; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Magnesium; Models, Molecular; Molecular Sequence Data; Oxazines; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xanthenes; Xanthones | 2003 |
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Topics: Antigens, Neoplasm; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; G1 Phase; HEK293 Cells; Humans; Mediator Complex; Mitogen-Activated Protein Kinase Kinases; Oxazines; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ets; Quinolones; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Topoisomerase Inhibitors; Transcription Factors; Up-Regulation | 2012 |